NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free BLTE Stock Alerts $43.19 -0.01 (-0.02%) (As of 11:42 AM ET) Add Compare Share Share Today's Range$42.00▼$43.2050-Day Range$32.33▼$47.0552-Week Range$11.00▼$48.60Volume13,175 shsAverage Volume55,119 shsMarket Capitalization$1.26 billionP/E RatioN/ADividend YieldN/APrice Target$44.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Belite Bio alerts: Email Address Belite Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3.8% Upside$44.83 Price TargetShort InterestHealthy0.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.63) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.63 out of 5 starsMedical Sector838th out of 905 stocksPharmaceutical Preparations Industry399th out of 422 stocks 1.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 1 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.12% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently decreased by 13.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 2.4 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Belite Bio this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Belite Bio are expected to decrease in the coming year, from ($0.63) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -34.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -34.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 13.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About Belite Bio Stock (NASDAQ:BLTE)Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Read More BLTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLTE Stock News HeadlinesMay 8, 2024 | globenewswire.comBelite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comBelite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 6, 2024 | globenewswire.comBelite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingMay 2, 2024 | seekingalpha.comBLTE Belite Bio, IncMay 2, 2024 | americanbankingnews.comBelite Bio, Inc (NASDAQ:BLTE) Receives Consensus Recommendation of "Buy" from AnalystsMay 1, 2024 | globenewswire.comBelite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingApril 27, 2024 | investing.comBelite Bio secures $25 million in registered direct offeringMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 25, 2024 | globenewswire.comBelite Bio Announces $25 Million Registered Direct OfferingApril 13, 2024 | morningstar.comBelite Bio Inc ADRMarch 23, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 22, 2024 | msn.comBelite Retreats On Start Of Clinical TrialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market PotentialMarch 22, 2024 | globenewswire.comBelite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 21, 2024 | markets.businessinsider.comBuy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong FinancialsMarch 20, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn SituationMarch 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)March 14, 2024 | nasdaq.comBelite Bio is Now Oversold (BLTE)March 14, 2024 | seekingalpha.comBelite Bio, Inc (BLTE) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)March 11, 2024 | globenewswire.comBelite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteMarch 11, 2024 | globenewswire.comBelite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 6, 2024 | globenewswire.comBelite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2024 | globenewswire.comBelite Bio to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 21, 2024 | benzinga.comBelite Bio Stock (NASDAQ:BLTE) Insider TradesFebruary 7, 2024 | finance.yahoo.comBelite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceSee More Headlines Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/08/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$44.83 High Stock Price Target$60.00 Low Stock Price Target$25.00 Potential Upside/Downside+3.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.05% Return on Assets-50.06% Debt Debt-to-Equity RatioN/A Current Ratio24.76 Quick Ratio24.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book13.17Miscellaneous Outstanding Shares29,149,000Free Float25,275,000Market Cap$1.26 billion OptionableNot Optionable Beta-1.52 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 45)Ph.D., Chairman of the Board of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Key CompetitorsProthenaNASDAQ:PRTAGyre TherapeuticsNASDAQ:GYREIronwood PharmaceuticalsNASDAQ:IRWDSpyre TherapeuticsNASDAQ:SYREPacira BioSciencesNASDAQ:PCRXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 36,000 shares on 2/13/2024Ownership: 0.130%View All Institutional Transactions BLTE Stock Analysis - Frequently Asked Questions Should I buy or sell Belite Bio stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLTE shares. View BLTE analyst ratings or view top-rated stocks. What is Belite Bio's stock price target for 2024? 7 brokerages have issued twelve-month target prices for Belite Bio's stock. Their BLTE share price targets range from $25.00 to $60.00. On average, they expect the company's share price to reach $44.83 in the next year. This suggests a possible upside of 3.8% from the stock's current price. View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts. How have BLTE shares performed in 2024? Belite Bio's stock was trading at $45.75 at the beginning of 2024. Since then, BLTE shares have decreased by 5.6% and is now trading at $43.19. View the best growth stocks for 2024 here. Are investors shorting Belite Bio? Belite Bio saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 34,000 shares, a decrease of 13.0% from the March 31st total of 39,100 shares. Based on an average daily trading volume, of 52,300 shares, the days-to-cover ratio is currently 0.7 days. View Belite Bio's Short Interest. When is Belite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BLTE earnings forecast. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) released its earnings results on Monday, March, 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.11. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLTE) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
